Predicting early treatment response in advanced liver cancer
Developing Atezolizumab-Bevacizumab Treatment Response Early Prediction Model in Advanced Hepatocellular Carcinoma Patients
This study is testing if a new way to combine two cancer treatments can help people with advanced liver cancer respond better than using each treatment alone.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 170 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Drugs / interventions | atezolizumab, bevacizumab |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05763277 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a predictive model for early response evaluation in patients with advanced hepatocellular carcinoma receiving atezolizumab-bevacizumab combination therapy. The study will compare treatment responses of this combination therapy against atezolizumab alone and bevacizumab alone. By identifying early indicators of treatment efficacy, the study seeks to improve patient management and outcomes. Participants will be monitored for their response to the therapy as part of the evaluation process.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with advanced hepatocellular carcinoma who are scheduled to receive atezolizumab-bevacizumab as their first-line therapy.
Not a fit: Patients with severe comorbidities or a history of severe contrast allergy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable earlier and more effective treatment decisions for patients with advanced liver cancer.
How similar studies have performed: While there have been studies on treatment responses in hepatocellular carcinoma, this specific predictive model approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy * Patients willing to participate in this study Exclusion Criteria: * Individuals with a history of severe contrast allergy * Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.)
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Jeong-Hoon Lee, MD PhD
- Email: pindra@empal.com
- Phone: +82-2-2072-2228
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.